Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

October 26-28, 2017

New York, New York
Sheraton New York

Continuing Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOC Successful completion of this CME activity enables a participant to earn up to 18.75 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Physician Assistants

This program has been reviewed and is approved for a maximum of 25.25 AAPA Category 1 CME credits by the AAPA Review Panel. PAs should claim only those credits actually spent participating in the CME activity.

This program was planned in accordance with AAPA CME Standards for Live Programs and for Commercial Support of Live Programs.

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 19.25 contact hours. Please check onsite for pharmacotherapeutic contact hours.

For questions about CNE, contact American Academy of CME, Inc.,
129 N County Line Road, Suite 6-329, Jackson, NJ 08527 or

It is the policy of Imedex®, LLC and the Academy to ensure balance, independence, objectivity, and scientific rigor in all provided or jointly provided educational activities. All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CME/CNE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. Financial relationships of the individual’s spouse or partner must also be disclosed, if the nature of the relationship could influence the objectivity of the individual in a position to control the content of the CME/CNE. The ACCME and ANCC describe relevant financial relationships as financial relationships in any amount that create a conflict of interest and that occurred in the twelve-month period preceding the time that the individual was asked to assume a role controlling content of the CME/CNE activity. Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CME/CNE activity.

ABIM MOC Imedex is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge activity (0408-0000-17-002-H01-P) has been approved for a maximum of 18.75 contact hours (1.875 CEUs). Successful completion of the activity includes participation within the activity and completion of an evaluation.

Who Should Attend

This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies.


Upon successful completion of these educational activities, participants should be better able to:

  • Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignancies
  • Define mechanisms of action of current and emerging agents for hematologic malignancies
  • Assess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignancies
  • Formulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, whose with poor functional capacity)
  • Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignancies
  • Evaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignancies